156 related articles for article (PubMed ID: 19925028)
21. Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding.
Wang W; Takimoto R; Rastinejad F; El-Deiry WS
Mol Cell Biol; 2003 Mar; 23(6):2171-81. PubMed ID: 12612087
[TBL] [Abstract][Full Text] [Related]
22. Functional inactivation of p73, a homolog of p53 tumor suppressor protein, by human papillomavirus E6 proteins.
Park JS; Kim EJ; Lee JY; Sin HS; Namkoong SE; Um SJ
Int J Cancer; 2001 Mar; 91(6):822-7. PubMed ID: 11275986
[TBL] [Abstract][Full Text] [Related]
23. The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein.
Takimoto R; Wang W; Dicker DT; Rastinejad F; Lyssikatos J; el-Deiry WS
Cancer Biol Ther; 2002; 1(1):47-55. PubMed ID: 12174820
[TBL] [Abstract][Full Text] [Related]
24. Mechanisms of differential activation of target gene promoters by p53 hinge domain mutants with impaired apoptotic function.
Kong XT; Gao H; Stanbridge EJ
J Biol Chem; 2001 Aug; 276(35):32990-3000. PubMed ID: 11395510
[TBL] [Abstract][Full Text] [Related]
25. Dysfunction of p53 pathway in human colorectal cancer: analysis of p53 gene mutation and the expression of the p53-associated factors p14ARF, p33ING1, p21WAF1 and MDM2.
Tachibana M; Kawamata H; Fujimori T; Omotehara F; Horiuchi H; Ohkura Y; Igarashi S; Kotake K; Kubota K
Int J Oncol; 2004 Oct; 25(4):913-20. PubMed ID: 15375540
[TBL] [Abstract][Full Text] [Related]
26. Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter.
Bian J; Sun Y
Mol Cell Biol; 1997 Nov; 17(11):6330-8. PubMed ID: 9343394
[TBL] [Abstract][Full Text] [Related]
27. p73 can suppress the proliferation of cells that express mutant p53.
Willis AC; Pipes T; Zhu J; Chen X
Oncogene; 2003 Aug; 22(35):5481-95. PubMed ID: 12934108
[TBL] [Abstract][Full Text] [Related]
28. Resistance of mitochondrial p53 to dominant inhibition.
Heyne K; Schmitt K; Mueller D; Armbruester V; Mestres P; Roemer K
Mol Cancer; 2008 Jun; 7():54. PubMed ID: 18547443
[TBL] [Abstract][Full Text] [Related]
29. Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene.
Chen J; Lin J; Levine AJ
Mol Med; 1995 Jan; 1(2):142-52. PubMed ID: 8529093
[TBL] [Abstract][Full Text] [Related]
30. Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes.
Scian MJ; Stagliano KE; Deb D; Ellis MA; Carchman EH; Das A; Valerie K; Deb SP; Deb S
Oncogene; 2004 May; 23(25):4430-43. PubMed ID: 15077194
[TBL] [Abstract][Full Text] [Related]
31. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM.
Song H; Hollstein M; Xu Y
Nat Cell Biol; 2007 May; 9(5):573-80. PubMed ID: 17417627
[TBL] [Abstract][Full Text] [Related]
32. Transcription factor E2F-1 is upregulated in response to DNA damage in a manner analogous to that of p53.
Blattner C; Sparks A; Lane D
Mol Cell Biol; 1999 May; 19(5):3704-13. PubMed ID: 10207094
[TBL] [Abstract][Full Text] [Related]
33. Characterisation of DNA binding and transcriptional regulatory function of an endogenous mutant p53 in MDA-468 human breast cancer cells.
Prasad KA; Church JG
Biochem Biophys Res Commun; 1997 Mar; 232(1):14-9. PubMed ID: 9125118
[TBL] [Abstract][Full Text] [Related]
34. Identification and functional characterization of the human glutathione S-transferase P1 gene as a novel transcriptional target of the p53 tumor suppressor gene.
Lo HW; Stephenson L; Cao X; Milas M; Pollock R; Ali-Osman F
Mol Cancer Res; 2008 May; 6(5):843-50. PubMed ID: 18505928
[TBL] [Abstract][Full Text] [Related]
35. p53 activation in chronic radiation-treated breast cancer cells: regulation of MDM2/p14ARF.
Xia L; Paik A; Li JJ
Cancer Res; 2004 Jan; 64(1):221-8. PubMed ID: 14729628
[TBL] [Abstract][Full Text] [Related]
36. How many mutant p53 molecules are needed to inactivate a tetramer?
Chan WM; Siu WY; Lau A; Poon RY
Mol Cell Biol; 2004 Apr; 24(8):3536-51. PubMed ID: 15060172
[TBL] [Abstract][Full Text] [Related]
37. Modulation of gene expression in U251 glioblastoma cells by binding of mutant p53 R273H to intronic and intergenic sequences.
Brázdová M; Quante T; Tögel L; Walter K; Loscher C; Tichý V; Cincárová L; Deppert W; Tolstonog GV
Nucleic Acids Res; 2009 Apr; 37(5):1486-500. PubMed ID: 19139068
[TBL] [Abstract][Full Text] [Related]
38. Identification of ANKRD11 as a p53 coactivator.
Neilsen PM; Cheney KM; Li CW; Chen JD; Cawrse JE; Schulz RB; Powell JA; Kumar R; Callen DF
J Cell Sci; 2008 Nov; 121(Pt 21):3541-52. PubMed ID: 18840648
[TBL] [Abstract][Full Text] [Related]
39. A transforming p53 mutant, which binds DNA, transactivates and induces apoptosis reveals a nuclear:cytoplasmic shuttling defect.
Crook T; Parker GA; Rozycka M; Crossland S; Allday MJ
Oncogene; 1998 Mar; 16(11):1429-41. PubMed ID: 9525742
[TBL] [Abstract][Full Text] [Related]
40. Fas-mediated apoptosis is dependent on wild-type p53 status in human cancer cells expressing a temperature-sensitive p53 mutant alanine-143.
Li Y; Raffo AJ; Drew L; Mao Y; Tran A; Petrylak DP; Fine RL
Cancer Res; 2003 Apr; 63(7):1527-33. PubMed ID: 12670900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
